Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma

Published:2017-07-20 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Rossetti Sabrina,D'Aniello Carmine,Iovane Gelsomina,Scagliarini Sarah,Laterza Maria M.,De Vita Fernando,Savastano Clementina,Cartenì Giacomo,Porricelli Maria A.,Berretta Massimiliano,Pisconti Salvatore,Facchini Gaetano,Cavaliere Carla

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma;Albiges;J. Clin. Oncol.,2012

2. Pazopanib in metastatic renal cancer: a “real-world” experience at National Cancer Institute “Fondazione, G. Pascale.”;Cecere;Front. Pharmacol.,2016

3. Alternating treatment with pazopanib and everolimus vs. continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: The ROPETAR Randomized Clinical Trial;Cirkel;JAMA Oncol.,2016

4. Metastatic renal cancer: prognostic and predictive biomarkers review;D'Aniello;World Cancer Res. J.

5. Long-term response to pazopanib in an elderly man with mRCC. A case report;D'Aniello;Tumori

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review;Translational Cancer Research;2020-04

2. Sequential treatment of metastatic renal cancer in a complex evolving landscape;Annals of Translational Medicine;2019-12

3. A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma;Bioscience Reports;2017-12-07

4. Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety;Future Oncology;2017-12